Here's the truth about AI. AI is only as powerful as the platform it's built into.

ServiceNow puts AI to work for people across your business, removing friction and frustration

for your employees, supercharging productivity for your developers, providing intelligent tools

for your service agents to make customers happier, all built into a single platform you can

use right now. That's why the world works with ServiceNow. Visit ServiceNow.com

slash UK slash AI for people. Welcome to Scientific American Science Talk posted on January 30th,

2017. I'm Steve Murski. On January 18th at the World Economic

Forum in Davos, Switzerland, the Coalition for Epidemic Preparedness Innovations, also known as

CEPI or CEPI, announced that it had raised an initial $460 million of backing from Norway, Germany, Japan,

the Welcome Trust, and the Bill and Melinda Gates Foundation. The organization expects to raise

the $1 billion that it needs for the next five years by the end of this year. As the journal

Nature put it, CEPi is thus the largest vaccine development

initiative ever against viruses that are potential epidemic threats. Scientific American

editor-in-chief Mariette de Cristina was at Davos and spoke briefly with Trevor Mundell. He's

the president of Global Health at the Gates Foundation.

They talked mostly about what's ahead for vaccine platforms.

That's the thing that's going to carry the antigen, which is what will get the immune system to spring into action.

What it sounds like they're hoping to do is get one or a few vaccine platforms, especially using nucleic acids, that could code for whatever antigen you need, so that if you have, for example, malaria in this part of the world, you pop in

the malaria antigen and start vaccinating. If you have Ebola in another part of the world,

you take the same platform, but switch in the Ebola antigen

instead of the malaria one. Obviously, that's a gross oversimplification, but that's the general

idea. According to nature, the first targets for CEPI are vaccines against the Nippa virus

...